Name the document as carefully as the product
Where the record begins.
These sources serve different purposes. Product pages describe advertised preparations and offers; exact labels, regulatory communications and professional guidance have their own limits. The article and preparation links show where each document enters the discussion.
Accessed 2026-09-27
CoreAge Rx Spot On product page
Provider commercial product description; named compound and care claims
Open the original documentArticles connected to this source
- CoreAge Rx Spot On face cream: the preparation behind the promise
- Hydroquinone face-cream routes: compare records before comparing strengths
- Hydroquinone percentages need a complete product name
- Compounded hydroquinone: identify the approval record precisely
- Hydroquinone follow-up: the details a sales page cannot supply
- Before a hydroquinone comparison, clarify the dark spot
Accessed 2026-09-27
CoreAge Rx Spot On current offer
Current public sales page; exact formula claims, plan cards and conflicting price statement
Open the original documentArticles connected to this source
Accessed 2026-09-27
FDA: Compounding and the FDA — Questions and Answers
Federal regulatory explanation; no provider-specific compliance determination
Open the original documentArticles connected to this source
- CoreAge Rx Spot On face cream: the preparation behind the promise
- Hydroquinone face-cream routes: compare records before comparing strengths
- Dermatica hydroquinone face cream: read the proposed formula, not just the ingredient menu
- Hydroquinone percentages need a complete product name
- Compounded hydroquinone: identify the approval record precisely
Accessed 2026-09-27
AAD: Melasma diagnosis and treatment
Professional society patient guidance; diagnosis and individualized treatment context, updated February 15, 2022
Open the original documentArticles connected to this source
- CoreAge Rx Spot On face cream: the preparation behind the promise
- Hydroquinone face-cream routes: compare records before comparing strengths
- Obagi Nu-Derm Clear Rx: keep the prescription record separate from Clear Fx
- Dermatica hydroquinone face cream: read the proposed formula, not just the ingredient menu
- Hydroquinone percentages need a complete product name
- Hydroquinone follow-up: the details a sales page cannot supply
- Before a hydroquinone comparison, clarify the dark spot
Accessed 2026-09-27
FDA: Potentially harmful OTC skin-lightening products
FDA communication dated April 19, 2022, currently checked; OTC status, adverse reports and exact Tri-Luma approval distinction
Open the original documentArticles connected to this source
- CoreAge Rx Spot On face cream: the preparation behind the promise
- Hydroquinone face-cream routes: compare records before comparing strengths
- Obagi Nu-Derm Clear Rx: keep the prescription record separate from Clear Fx
- Dermatica hydroquinone face cream: read the proposed formula, not just the ingredient menu
- Compounded hydroquinone: identify the approval record precisely
- Before a hydroquinone comparison, clarify the dark spot
Accessed 2026-09-27
AAD: Rash 101: When to seek medical treatment
Professional society general rash warning guidance; updated January 22, 2024
Open the original documentArticles connected to this source
Accessed 2026-09-27
Obagi Nu-Derm Clear prescription cream
Manufacturer product and ingredient record; prescription route and product-specific safety information
Open the original documentArticles connected to this source
Accessed 2026-09-27
Obagi Nu-Derm Clear Fx Skin Brightening Cream
Separate manufacturer retail product record; arbutin formula and price do not identify Clear Rx
Open the original documentArticles connected to this source
Accessed 2026-09-27
Dermatica: Melasma personalized treatment
Provider ingredient menu and service claims; not an individual prescription
Open the original documentArticles connected to this source
Accessed 2026-09-27
Dermatica: Pricing
Provider plan and delivery terms
Open the original documentArticles connected to this source
Accessed 2026-09-27
Dermatica US homepage
Provider compound description and trial offer
Open the original documentArticles connected to this source
Accessed 2026-09-27
Dermatica: Terms and conditions
Provider terms; page states February 4, 2019 revision, freshly accessed; platform and clinical roles
Open the original documentArticles connected to this source
Accessed 2026-09-27
DailyMed: TRI-LUMA prescribing information
Exact Galderma combination label; record updated October 24, 2024, prescribing information revised February 2023
Open the original documentArticles connected to this source
Accessed 2026-09-27
AAD: How to fade dark spots in darker skin tones
Patient guidance updated March 10, 2025; possible causes and cause-specific assessment, not a diagnostic tool
Open the original documentArticles connected to this source
Accessed 2026-09-27
AAD: What to look for in the ABCDEs of melanoma
Professional-society guidance about new, different, changing, itching or bleeding spots; no diagnostic scoring reproduced
Open the original documentArticles connected to this source
Accessed 2026-09-27
FDA: National Drug Code Directory
Official directory scope and explicit nonapproval and unverified-submission limitations
Open the original documentArticles connected to this source
Accessed 2026-09-27
FDA: Pharmacists Help You Use Medicines Safely
Official guidance on medicine questions, medication history and pharmacist communication; no personal compatibility conclusion
Open the original document